Table 3.
Treatment categories
Pembro pembrolizumab; Ate atezolizumab; Doc docetaxel; Erl erlotinib; Nin nintedanib; Ram ramucirumab; Cabo cabozantinib
The direction of the reported relative effects in each cell is defined as treatment on the right vs. treatment on the left. Values < 1 favor the intervention on the right. Values in parenthesis are 95% credible intervals (95% CrIs). Colored cells correspond to statistically significant relative effects for the respective treatment categories. For instance, cabozantinib was more effective than docetaxel in terms of PFS (HR 0.42 (95% CrI 0.20-0.87)